Comparative Pharmacology
Head-to-head clinical analysis: KENALOG 80 versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG 80 versus STERANE.
KENALOG-80 vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-proliferative effects. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, which reduces prostaglandin and leukotriene synthesis. It also suppresses cytokine production and immune cell migration.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
60 mg (1.5 mL) intramuscularly (deep IM) as a single dose for allergic/ inflammatory conditions; intra-articular or soft tissue injection: 10-40 mg for large joints, 5-25 mg for medium joints, 2.5-10 mg for small joints; intralesional: up to 1 mg per injection site, repeated as needed.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life: 2–4 hours for triamcinolone acetonide; prolonged in hepatic impairment (up to 6–8 hours).
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine, with minor biliary/fecal elimination (<2%).
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid